Peter Marks’ Departure From FDA Rattles Biopharma Industry

XBI Reaches A New 2025 Low

 
• By Mandy Jackson
  
FDA review of vaccines and cell and gene therapies could be held up under new CBER leadership (Shutterstock)

More from Strategy

More from Scrip